

Walter J Storkus

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1898024/walter-j-storkus-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

151
papers

7,184
citations

48
h-index

80
g-index

162
ext. papers

7,934
ext. citations

7.4
avg, IF

5.38
L-index

#	Paper	IF	Citations
151	Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma 2021, 9,		2
150	PET Imaging of VLA-4 in a New BRAF Mouse Model of Melanoma. <i>Molecular Imaging and Biology</i> , 2021, 1	3.8	2
149	Cutaneous Melanoma: Mutational Status and Potential Links to Tertiary Lymphoid Structure Formation. <i>Frontiers in Immunology</i> , 2021, 12, 629519	8.4	4
148	RGS5-TGFβSmad2/3 axis switches pro- to anti-apoptotic signaling in tumor-residing pericytes, assisting tumor growth. <i>Cell Death and Differentiation</i> , 2021, 28, 3052-3076	12.7	2
147	STING Agonists as Cancer Therapeutics. <i>Cancers</i> , 2021, 13,	6.6	25
146	STINGing the Tumor Microenvironment to Promote Therapeutic Tertiary Lymphoid Structure Development. <i>Frontiers in Immunology</i> , 2021, 12, 690105	8.4	6
145	Unbiased High-Throughput Drug Combination Pilot Screening Identifies Synergistic Drug Combinations Effective against Patient-Derived and Drug-Resistant Melanoma Cell Lines. <i>SLAS Discovery</i> , 2021, 26, 712-729	3.4	1
144	Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors 2021, 9,		2
143	STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment 2021, 9,		13
142	Epigenetic modulation of antitumor immunity for improved cancer immunotherapy.. <i>Molecular Cancer</i> , 2021, 20, 171	42.1	6
141	Tumor Arrests DN2 to DN3 Pro T Cell Transition and Promotes Its Conversion to Thymic Dendritic Cells by Reciprocally Regulating Notch1 and Ikaros Signaling. <i>Frontiers in Immunology</i> , 2020, 11, 898	8.4	4
140	Neopeptides as Difference Makers for General Cancer Vaccines?. <i>Clinical Cancer Research</i> , 2020, 26, 4429-4431	11.9	1
139	IL-36 Signaling in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1240, 95-110	3.6	3
138	Single injection of IL-12 coacervate as an effective therapy against B16-F10 melanoma in mice. <i>Journal of Controlled Release</i> , 2020, 318, 270-278	11.7	14
137	Dysregulated NF-κB-Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma. <i>Cancer Immunology Research</i> , 2020, 8, 1554-1567	12.5	6
136	Actin-binding protein profilin1 promotes aggressiveness of clear-cell renal cell carcinoma cells. <i>Journal of Biological Chemistry</i> , 2020, 295, 15636-15649	5.4	7
135	Tumor-derived exosomes promote carcinogenesis of murine oral squamous cell carcinoma. <i>Carcinogenesis</i> , 2020, 41, 625-633	4.6	31

134	Impact of combination immunochemotherapies on progression of 4NQO-induced murine oral squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 1133-1141	7.4	5
133	Inhibiting Autophagy in Renal Cell Cancer and the Associated Tumor Endothelium. <i>Cancer Journal (Sudbury, Mass)</i> , 2019 , 25, 165-177	2.2	5
132	Association of IL-36 β with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 109-120	7.4	37
131	Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 1843-1849	8.9	32
130	Inhibition of HSPs for Enhanced Immunity 2018 , 157-180		
129	Therapeutic efficacy of combined vaccination against tumor pericyte-associated antigens DLK1 and DLK2 in mice. <i>Oncolmunology</i> , 2017 , 6, e1290035	7.2	10
128	Tumor-Derived β Fetoprotein Directly Drives Human Natural Killer-Cell Activation and Subsequent Cell Death. <i>Cancer Immunology Research</i> , 2017 , 5, 493-502	12.5	12
127	Tbet and IL-36 β cooperate in therapeutic DC-mediated promotion of ectopic lymphoid organogenesis in the tumor microenvironment. <i>Oncolmunology</i> , 2017 , 6, e1322238	7.2	37
126	Intratumoral delivery of tumor antigen-loaded DC and tumor-primed CD4 T cells combined with agonist β GITR mAb promotes durable CD8 T-cell-dependent antitumor immunity. <i>Oncolmunology</i> , 2017 , 6, e1315487	7.2	11
125	Immunotherapeutic Targeting of Tumor-Associated Blood Vessels. <i>Advances in Experimental Medicine and Biology</i> , 2017 , 1036, 191-211	3.6	11
124	Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines. <i>Immunotherapy</i> , 2016 , 8, 1205-18	3.8	10
123	Tumor-associated mesenchymal stem cells inhibit naive T cell expansion by blocking cysteine export from dendritic cells. <i>International Journal of Cancer</i> , 2016 , 139, 2068-81	7.5	19
122	miR-29b and miR-198 overexpression in CD8+ T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction. <i>Journal of Translational Medicine</i> , 2016 , 14, 84	8.5	24
121	Vascular Normalization, T Cell Trafficking and Anti-tumor Immunity. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2016 , 51-76	0.3	
120	Biosynthesis and Functional Significance of Peripheral Node Addressin in Cancer-Associated TLO. <i>Frontiers in Immunology</i> , 2016 , 7, 301	8.4	10
119	Intratumoral delivery of mTORC2-deficient dendritic cells inhibits B16 melanoma growth by promoting CD8(+) effector T cell responses. <i>Oncolmunology</i> , 2016 , 5, e1146841	7.2	19
118	Genetic vaccines to potentiate the effective CD103+ dendritic cell-mediated cross-priming of antitumor immunity. <i>Journal of Immunology</i> , 2015 , 194, 5937-47	5.3	24
117	IL-36 β Transforms the Tumor Microenvironment and Promotes Type 1 Lymphocyte-Mediated Antitumor Immune Responses. <i>Cancer Cell</i> , 2015 , 28, 296-306	24.3	62

116	Pilot trial of a type I - polarized autologous dendritic cell vaccine incorporating tumor blood vessel antigen-derived peptides in patients with metastatic breast cancer 2015 , 3,		78
115	Therapeutic Lymphoid Organogenesis in the Tumor Microenvironment. <i>Advances in Cancer Research</i> , 2015 , 128, 197-233	5.9	33
114	Vaccines in RCC: Clinical and Biological Relevance 2015 , 483-525		
113	Circulating Type-1 Anti-Tumor CD4(+) T Cells are Preferentially Pro-Apoptotic in Cancer Patients. <i>Frontiers in Oncology</i> , 2014 , 4, 266	5.3	15
112	Molecular mimicry of MAGE-A6 and HF-2 epitopes in the induction of antitumor CD8 T-cell responses. <i>Oncolimmunology</i> , 2014 , 3, e954501	7.2	13
111	Dendritic cell-derived interleukin-15 is crucial for therapeutic cancer vaccine potency. <i>Oncolimmunology</i> , 2014 , 3, e959321	7.2	14
110	Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma. <i>Oncolimmunology</i> , 2014 , 3, e27589	7.2	29
109	Monitoring antigen-specific T cell responses using real-time PCR. <i>Methods in Molecular Biology</i> , 2014 , 1186, 65-74	1.4	1
108	DLK1: a novel target for immunotherapeutic remodeling of the tumor blood vasculature. <i>Molecular Therapy</i> , 2013 , 21, 1958-68	11.7	23
107	Therapeutic use of dendritic cells to promote the extranodal priming of anti-tumor immunity. <i>Frontiers in Immunology</i> , 2013 , 4, 388	8.4	21
106	Tumor-derived vascular pericytes anergize Th cells. <i>Journal of Immunology</i> , 2013 , 191, 971-81	5.3	52
105	Neurokinin-1 receptor agonists bias therapeutic dendritic cells to induce type 1 immunity by licensing host dendritic cells to produce IL-12. <i>Blood</i> , 2013 , 121, 2923-33	2.2	37
104	Molecular Immunotherapeutics and Vaccines for Renal Cell Carcinoma and Its Vasculature 2013 , 371-383		
103	Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape. <i>Immunological Investigations</i> , 2012 , 41, 680-710	2.9	33
102	Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model. <i>Melanoma Research</i> , 2012 , 22, 236-43	3.3	51
101	Combined Tbet and IL12 gene therapy elicits and recruits superior antitumor immunity in vivo. <i>Molecular Therapy</i> , 2012 , 20, 644-51	11.7	7
100	Shock block for improved immunotherapy. <i>Oncolimmunology</i> , 2012 , 1, 1427-1429	7.2	5
99	Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice. <i>Journal of Immunology</i> , 2012 , 188, 1782-8	5.3	36

98	Combination therapy with HSP90 inhibitor 17-DMAG reconditions the tumor microenvironment to improve recruitment of therapeutic T cells. <i>Cancer Research</i> , 2012 , 72, 3196-206	10.1	43
97	Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. <i>International Journal of Cancer</i> , 2011 , 129, 2158-70	7.5	112
96	Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens. <i>Molecular Therapy</i> , 2011 , 19, 805-14	11.7	32
95	Chronic inflammation and immunologic-based constraints in malignant disease. <i>Immunotherapy</i> , 2011 , 3, 1265-74	3.8	44
94	Update on vaccine development for renal cell cancer. <i>Research and Reports in Urology</i> , 2010 , 2, 125-41	1.3	3
93	Intralesional delivery of dendritic cells engineered to express T-bet promotes protective type 1 immunity and the normalization of the tumor microenvironment. <i>Journal of Immunology</i> , 2010 , 185, 2895-902	5.3	14
92	JAK3/STAT5/6 pathway alterations are associated with immune deviation in CD8 T cells in renal cell carcinoma patients. <i>Journal of Biomedicine and Biotechnology</i> , 2010 , 2010, 935764		20
91	A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment. <i>Cancer Research</i> , 2010 , 70, 9041-52	10.1	36
90	DC expressing transgene Foxp3 are regulatory APC. <i>European Journal of Immunology</i> , 2010 , 40, 480-93	6.1	21
89	Generation of robust CD8+ T-cell responses against subdominant epitopes in conserved regions of HIV-1 by repertoire mining with mimotopes. <i>European Journal of Immunology</i> , 2010 , 40, 1950-62	6.1	12
88	Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes. <i>Journal of Immunology</i> , 2009 , 183, 3720-30	5.3	381
87	Ectopic T-bet expression licenses dendritic cells for IL-12-independent priming of type 1 T cells in vitro. <i>Journal of Immunology</i> , 2009 , 183, 7250-8	5.3	28
86	Heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin enhances EphA2+ tumor cell recognition by specific CD8+ T cells. <i>Cancer Research</i> , 2009 , 69, 6995-7003	10.1	31
85	Integrating costimulatory agonists to optimize immune-based cancer therapies. <i>Immunotherapy</i> , 2009 , 1, 249-64	3.8	11
84	IL-4 suppresses very late antigen-4 expression which is required for therapeutic Th1 T-cell trafficking into tumors. <i>Journal of Immunotherapy</i> , 2009 , 32, 793-802	5	22
83	EphA2: A Novel Target in Renal Cell Carcinoma 2009 , 347-366		0
82	Dendritic Cell Maturation Versus Polarization in Tumor Escape 2009 , 257-268		
81	Focus on FOCIS: interleukin 2 treatment associated autoimmunity. <i>Clinical Immunology</i> , 2008 , 127, 123-99		13

80	Enhancement in specific CD8+ T cell recognition of EphA2+ tumors in vitro and in vivo after treatment with ligand agonists. <i>Journal of Immunology</i> , 2008 , 181, 7721-7	5.3	24
79	CD8+ T-cell responses against hemoglobin-beta prevent solid tumor growth. <i>Cancer Research</i> , 2008 , 68, 8076-84	10.1	23
78	Stat6 signaling suppresses VLA-4 expression by CD8+ T cells and limits their ability to infiltrate tumor lesions in vivo. <i>Journal of Immunology</i> , 2008 , 181, 104-8	5.3	25
77	Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients. <i>Journal of Immunotherapy</i> , 2008 , 31, 254-62	5	41
76	IL-4 inhibits VLA-4 expression on Tc1 cells resulting in poor tumor infiltration and reduced therapy benefit. <i>European Journal of Immunology</i> , 2008 , 38, 2865-73	6.1	17
75	Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. <i>Journal of Translational Medicine</i> , 2007 , 5, 10	8.5	139
74	Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines. <i>Cancer</i> , 2007 , 110, 1469-77	6.4	42
73	Treatment-enhanced CD4+Foxp3+ glucocorticoid-induced TNF receptor family related high regulatory tumor-infiltrating T cells limit the effectiveness of cytokine-based immunotherapy. <i>Journal of Immunology</i> , 2007 , 178, 3400-8	5.3	7
72	Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity. <i>Cancer Research</i> , 2007 , 67, 10012-8	10.1	26
71	Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics. <i>Journal of Immunotherapy</i> , 2007 , 30, 577-90	5	2
70	A mycoplasma peptide elicits heteroclitic CD4+ T cell responses against tumor antigen MAGE-A6. <i>Clinical Cancer Research</i> , 2007 , 13, 6796-806	12.9	23
69	Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors. <i>Cancer Research</i> , 2007 , 67, 6451-8	10.1	53
68	Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4+ T cell responses in vitro. <i>Journal of Immunotherapy</i> , 2007 , 30, 75-82	5	73
67	Improving immunotherapy by conditionally enhancing MHC class I presentation of tumor antigen-derived Peptide epitopes. <i>Critical Reviews in Immunology</i> , 2007 , 27, 485-93	1.8	10
66	Combinational FLT3 ligand and granulocyte macrophage colony-stimulating factor treatment promotes enhanced tumor infiltration by dendritic cells and antitumor CD8(+) T-cell cross-priming but is ineffective as a therapy. <i>Cancer Research</i> , 2006 , 66, 4895-903	10.1	26
65	Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved anti glioma CTL responses. <i>Cancer Research</i> , 2006 , 66, 5883-91	10.1	53
64	Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10. <i>Cancer Research</i> , 2006 , 66, 4478-87	10.1	70
63	Accumulation of low-avidity anti-melanocortin receptor 1 (anti-MC1R) CD8+ T cells in the lesional skin of a patient with melanoma-related depigmentation. <i>Melanoma Research</i> , 2006 , 16, 165-74	3.3	7

62	Helper role of NK cells during the induction of anticancer responses by dendritic cells. <i>Molecular Immunology</i> , 2005 , 42, 535-9	4.3	96
61	Human papillomavirus L1L2-E7 virus-like particles partially mature human dendritic cells and elicit E7-specific T-helper responses from patients with cervical intraepithelial neoplasia or cervical cancer in vitro. <i>Human Immunology</i> , 2005 , 66, 762-72	2.3	14
60	EBV-specific memory CD8+ T cell phenotype and function in stable solid organ transplant patients. <i>Transplant Immunology</i> , 2005 , 14, 109-16	1.7	26
59	EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. <i>Neoplasia</i> , 2005 , 7, 717-22	6.4	112
58	IL-12 production by human monocyte-derived dendritic cells: looking at the single cell. <i>Journal of Immunotherapy</i> , 2005 , 28, 306-13	5	13
57	Augmentation of type-1 polarizing ability of monocyte-derived dendritic cells from chronically immunosuppressed organ-transplant recipients. <i>Transplantation</i> , 2005 , 79, 451-9	1.8	12
56	IL-4-transfected tumor cell vaccines activate tumor-infiltrating dendritic cells and promote type-1 immunity. <i>Journal of Immunology</i> , 2005 , 174, 7194-201	5.3	30
55	Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways. <i>Journal of Immunology</i> , 2005 , 175, 2730-40	5.3	48
54	Nitric oxide sensitizes tumor cells to dendritic cell-mediated apoptosis, uptake, and cross-presentation. <i>Cancer Research</i> , 2005 , 65, 8461-70	10.1	50
53	Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. <i>Clinical Cancer Research</i> , 2005 , 11, 226-31	12.9	63
52	Effect of renal cell carcinomas on the development of type 1 T-cell responses. <i>Clinical Cancer Research</i> , 2004 , 10, 6360S-6S	12.9	62
51	Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines. <i>Cancer Research</i> , 2004 , 64, 5830-8	10.1	38
50	Ectopic expression of interferon regulatory factor-1 promotes human breast cancer cell death and results in reduced expression of survivin. <i>Cancer Research</i> , 2004 , 64, 8381-8	10.1	54
49	Disease-stage variance in functional CD4(+) T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes. <i>Clinical Cancer Research</i> , 2004 , 10, 3301-8	12.9	26
48	alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. <i>Cancer Research</i> , 2004 , 64, 5934-7	10.1	413
47	Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors. <i>Journal of Translational Medicine</i> , 2004 , 2, 40	8.5	46
46	CD4+ T-Cell-Mediated Immunity to Cancer 2004 , 67-86		1
45	Ex vivo priming of naive T cells into EBV-specific Th1/Tc1 effector cells by mature autologous DC loaded with apoptotic/necrotic LCL. <i>American Journal of Transplantation</i> , 2003 , 3, 1369-77	8.7	18

44	Melanocyte-specific immune response in melanoma and vitiligo: two faces of the same coin?. <i>Pigment Cell & Melanoma Research</i> , 2003 , 16, 254-60		40
43	Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-beta gene vector and dendritic cells. <i>Cancer Gene Therapy</i> , 2003 , 10, 549-58	5.4	26
42	Immunopolarization of CD4+ and CD8+ T cells to Type-1-like is associated with melanocyte loss in human vitiligo. <i>Laboratory Investigation</i> , 2003 , 83, 683-95	5.9	181
41	Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. <i>Journal of Immunology</i> , 2003 , 171, 2366-73	5.3	300
40	Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. <i>Cancer Research</i> , 2003 , 63, 4481-9	10.1	97
39	Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. <i>Cancer Research</i> , 2003 , 63, 6378-86	10.1	88
38	Application of IL-5 ELISPOT assays to quantification of antigen-specific T helper responses. <i>Journal of Immunological Methods</i> , 2002 , 261, 145-56	2.5	32
37	Progenipoiectin-generated dendritic cells exhibit anti-tumor efficacy in a therapeutic murine tumor model. <i>International Journal of Cancer</i> , 2002 , 100, 586-91	7.5	5
36	Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-alpha(1)beta(2), Fas ligand, and TNF-related apoptosis-inducing ligand. <i>Journal of Immunology</i> , 2002 , 168, 1831-9	5.3	119
35	Complementary dendritic cell-activating function of CD8+ and CD4+ T cells: helper role of CD8+ T cells in the development of T helper type 1 responses. <i>Journal of Experimental Medicine</i> , 2002 , 195, 473-83	16.6	129
34	Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. <i>Journal of Experimental Medicine</i> , 2002 , 196, 619-28	16.6	263
33	Innate direct anticancer effector function of human immature dendritic cells. I. Involvement of an apoptosis-inducing pathway. <i>Journal of Immunology</i> , 2002 , 168, 1823-30	5.3	76
32	Dendritic cell-based vaccines and therapies for cancer. <i>Expert Opinion on Biological Therapy</i> , 2002 , 2, 919-28	5.4	13
31	Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. <i>Clinical Cancer Research</i> , 2002 , 8, 1787-93	12.9	96
30	Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. <i>Clinical Cancer Research</i> , 2002 , 8, 2851-5	12.9	87
29	Interleukin 18 gene transfer expands the repertoire of antitumor Th1-type immunity elicited by dendritic cell-based vaccines in association with enhanced therapeutic efficacy. <i>Cancer Research</i> , 2002 , 62, 5853-8	10.1	38
28	Proinflammatory Cytokines and CD40 Ligand Enhance Cross-Presentation and Cross-Priming Capability of Human Dendritic Cells Internalizing Apoptotic Cancer Cells. <i>Journal of Immunotherapy</i> , 2001 , 24, 162-171	5	52
27	Ex vivo generation of effective Epstein-Barr virus (EBV)-specific CD8+ cytotoxic T lymphocytes from the peripheral blood of immunocompetent Epstein Barr virus-seronegative individuals. <i>Transplantation</i> , 2000 , 70, 1507-15	1.8	25

26	Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4+ and CD8+ T lymphocyte responses. <i>Blood</i> , 2000 , 96, 1857-1864	2.2	115
25	Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines. <i>Vaccine Journal</i> , 2000 , 7, 145-54		79
24	Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading. <i>Immunological Investigations</i> , 2000 , 29, 121-5	2.9	56
23	The immunology of DNA vaccines. <i>Methods in Molecular Medicine</i> , 2000 , 29, 37-64		2
22	Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice. <i>Cancer Gene Therapy</i> , 1999 , 6, 73-80	5.4	65
21	Interleukin-12 gene therapy prevents establishment of SCC VII squamous cell carcinomas, inhibits tumor growth, and elicits long-term antitumor immunity in syngeneic C3H mice. <i>Laryngoscope</i> , 1998 , 108, 261-8	3.6	28
20	DNA immunization targeting the skin: molecular control of adaptive immunity. <i>Journal of Investigative Dermatology</i> , 1998 , 111, 183-8	4.3	79
19	Autologous human dendrophages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTLs in vitro. <i>Journal of Immunotherapy</i> , 1998 , 21, 149-57	5	40
18	FLT3 ligand induces the generation of functionally active dendritic cells in mice. <i>Cellular Immunology</i> , 1997 , 179, 174-84	4.4	174
17	Gene-based strategies for the immunotherapy of cancer. <i>Journal of Molecular Medicine</i> , 1997 , 75, 478-915	5.5	55
16	Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo. <i>European Journal of Immunology</i> , 1997 , 27, 2702-7	6.1	109
15	Dendritic cell based therapy of cancer. <i>Advances in Experimental Medicine and Biology</i> , 1997 , 417, 551-69	3.6	35
14	Murine models of cancer cytokine gene therapy using interleukin-12. <i>Annals of the New York Academy of Sciences</i> , 1996 , 795, 275-83	6.5	32
13	IL-12-engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo. <i>Annals of the New York Academy of Sciences</i> , 1996 , 795, 284-93	6.5	79
12	Cytokine gene therapy of cancer using interleukin-12: murine and clinical trials. <i>Annals of the New York Academy of Sciences</i> , 1996 , 795, 440-54	6.5	62
11	Class I-like CD1A-C do not protect target cells from NK-mediated cytotoxicity. <i>Cellular Immunology</i> , 1996 , 167, 154-6	4.4	6
10	Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. <i>European Journal of Immunology</i> , 1996 , 26, 1335-41	6.1	122
9	Amino acid substitutions at position 97 in HLA-A2 segregate cytotoxicity from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes. <i>European Journal of Immunology</i> , 1996 , 26, 2613-23	6.1	5

8	Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes. <i>Cancer Immunology, Immunotherapy</i> , 1995 , 41, 111-21	7.4	66
7	IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. <i>Human Gene Therapy</i> , 1995 , 6, 1607-24	4.8	60
6	Host immune response in renal cell cancer: Interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes 1995 , 41, 111		1
5	Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. <i>Human Gene Therapy</i> , 1994 , 5, 1493-506	4.8	117
4	Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay. <i>European Journal of Immunology</i> , 1994 , 24, 765-8	6.1	61
3	Flow-cytometric determination of peptide-class I complex formation. Identification of p53 peptides that bind to HLA-A2. <i>Human Immunology</i> , 1994 , 39, 79-86	2.3	61
2	Identification of T-Cell Epitopes. <i>Journal of Immunotherapy</i> , 1993 , 14, 94-103	5	188
1	Human Tumor Antigens as Targets of Immunosurveillance and Candidates for Cancer Vaccines23-43		3